Hello. My name is Ashley, and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to the Danaher Corporation Fourth Quarter 2021 Earnings Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. I will now turn the call over to Mr. Matt Gugino, Vice President of Investor Relations. Mr. Gugino, you may begin your conference.

Thank you, Ashley. Good morning, everyone, and thanks for joining us on the call. With us today are Rainer Blair, our President and Chief Executive Officer; Matt McGrew, our Executive Vice President and Chief Financial Officer; and John Bedford, our Director of Investor Relations. I'd like to point out that our earnings release, the slide presentation supplementing today's call and the reconciliations and other information required by SEC Regulation G relating to any non-GAAP financial measures provided during the call are all available on the Investors section of our website, www.danaher.com, under the heading Quarterly Earnings. The audio portion of this call will be archived on the Investors section of our website later today under the heading Events and Presentations and will remain archived until our next quarterly call. A replay of this call will also be available until February 10, 2022. During the presentation, we will describe certain of the more significant factors that impacted year-over-year performance. The supplemental materials describe additional factors that impacted year-over-year performance. Unless otherwise noted, all references in these remarks and supplemental materials to company-specific financial metrics refer to results from continuing operations and relate to the fourth quarter of 2021, and all references to period-to-period increases or decreases in financial metrics are year-over-year. We may also describe certain products and devices which have applications submitted and pending for certain regulatory approvals or are available only in certain markets. During the call, we will make forward-looking statements within the meaning of the federal securities laws, including statements regarding events or developments that we believe or anticipate will or may occur in the future. These forward-looking statements are subject to a number of risks and uncertainties, including those set forth in our SEC filings, and actual results might differ materially from any forward-looking statements that we make today. These forward-looking statements speak only as of the date they are made, and we do not assume any obligation to update any forward-looking statements, except as required by law. With that, I'd like to turn the call over to Rainer.

Well, thanks, Matt, and good morning, everyone. We appreciate you joining us on the call today. 2021 was a tremendous year for Danaher capped off by a very strong finish to the fourth quarter. Our well-rounded performance throughout the year was highlighted by outstanding core revenue and earnings growth as well as strong free cash flow generation. We're particularly pleased with the strength of our base business across the portfolio, which was up low double digits for the year. We believe our accelerated innovation and capacity expansion initiatives have helped us capture market share at several of our businesses. Now these results are a testament to our team of 80,000 associates and their outstanding execution in what has been a challenging operating environment. Despite the uncertainty that has come to characterize life for all of us throughout the pandemic, our associates are showing up big every day, working longer shifts, launching breakthrough products in record time and going above and beyond to support our customers, and they remain committed as ever to executing with the Danaher Business System. Really, their dedication to serving our customers and the global community is as humbling as it is inspiring, and we're grateful for their invaluable contribution. The circumstances over the last several years have also shined a light on the high-quality, market-leading franchises and technologies that now comprise Danaher. We're seeing the results of our purpose-driven portfolio transformation in action today through higher growth in margins, stronger cash flow and a higher percentage of recurring revenue. We're exceptionally well positioned to continue this trajectory going forward, and we see a very bright future ahead indeed. So with that, let's take a closer look at our full year 2021 financial results. We delivered 25% core revenue growth, 560 basis points of core operating margin expansion, nearly 60% adjusted earnings per share growth and over $7 billion of free cash flow. We deployed $11 billion of capital towards acquisitions, closing 14 deals across all four of our platforms. The largest acquisition, Aldevron, joined our Life Sciences segment in August, providing a fantastic beachhead for us in the important frontier of genomic medicine. It's just a great example of how we're using strategic M&A to enhance our capability and bring greater value to our customers. Now throughout the year, we also made significant organic investments to accelerate innovation across our businesses. Our R&D spend was up approximately 30% year-over-year and is now more than $1.7 billion annually. New products, such as the SCIEX ZenoTOF 7600 and Triple Quad 7500 and Leica Biosystems Aperio GT 450 digital pathology slide scanner are driving share gains in their respective markets through proprietary innovation while further enhancing our growth trajectory. Now total capital expenditures were $1.3 billion for the year, which reflects substantial investments to expand production capacity across our businesses, particularly at Cepheid, Pall and Cytiva. In bioprocessing, I'm really happy to report that our new single-use technology plants in South Carolina and Beijing and our cell culture media expansion in Utah all came online in the fourth quarter. At Cepheid, we more than doubled our production capacity for respiratory tests in 2021. For the near term, we believe these investments have been critical to support customer demand, and they helped us achieve meaningful market share gains. And they're equally important in the long run to support the significant growth opportunities we see ahead in these very attractive end markets. Now let's spend some time on the fourth quarter results. Our sales were $8.1 billion, and we delivered 19.5% core revenue growth with strong contributions from all three segments. We saw broad-based strength across our base business, which was up approximately 10% in the quarter. Geographically, both developed and high-growth markets were up approximately 20% led by nearly 25% growth in North America and high teens growth in China. Gross profit margin was 60.7%, and our operating profit margin of 26.4% was up 270 basis points, including 240 basis points of core margin expansion. Adjusted diluted net earnings per share of $2.69 were up approximately 30%. For the full year, we generated more than $7 billion of free cash flow, up 30% year-over-year. In fact, our free cash flow to net income conversion was 112% for the full year, and it marks the 30th consecutive year this figure has exceeded 100% for Danaher. So now let's go into more detail on our quarterly results across the segment. Life Sciences reported revenue increased 20.5% with core revenue up 17%. These strong results were broad-based with most major operating companies achieving low double-digit or better core growth. In fact, Aldevron delivered over 30% revenue growth in the quarter and finished the year with approximately $400 million in total revenue. That business is off to a great start as part of Danaher, and we couldn't be more pleased with the team's performance out of the gate. Our core revenue growth in our processing businesses continued to outpace segment level results with Cytiva and Pall Biotech, both up more than 25%. Non-COVID-related bioprocessing trends remained strong with our businesses growing low double digits again this quarter. We continue to support significant customer activity across the development and production of COVID vaccines and therapeutics, which drove $2 billion of revenue in 2021. Moving to Diagnostics, reported revenue was up 29.5% and core revenue grew 29% led by greater than 75% core growth at Cepheid. Non-COVID clinical diagnostic activity across all our operating companies, including Beckman Coulter Diagnostics, Radiometer and Leica Biosystems collectively drove high single-digit core growth as patient and testing volumes largely remained at or near pre-pandemic levels. We also saw an acceleration in demand that crosses the non-respiratory menu, led by telehealth, hospital-acquired infections, and urology testing. Cepheid produced and shipped approximately $19 million of respiratory test cartridges during the quarter. This brought the total number of respiratory tests shipped in 2021 to approximately 16 million cartridges, more than 10 times the number of tests produced and shipped in 2019 prior to the start of the pandemic. In fact, our four-in-one combination test for COVID-19, Flu A, Flu B, and RSV represented approximately 50% of Q4 respiratory test shipments, while our COVID-only test accounted for the remainder. Now let's move on to our Environmental & Applied Solutions segment. Reported revenue was up 4%, with 7.5% core revenue growth. Our water quality and product identification platforms both delivered high single-digit core growth for the quarter. Across our water quality businesses, strength was broad-based globally across industrial and municipal end markets. Customer activity accelerated with the support of a strong funding environment, and many projects that were put on hold during the pandemic have now resumed. Country delivered low double-digit core revenue growth in the quarter to close out its 53rd consecutive year of growth. This is a tremendous accomplishment and a testament to the team's best-in-class commercial execution and commitment to continuous improvement. In Product Identification, our packaging and color management businesses were up mid-single digits and marking and coding was up approximately 10%. Videojet had its third consecutive quarter of double-digit core growth, led by strong demand in industrial and food and beverage end markets. With that backdrop for what we saw in the quarter, let me highlight the trends we're seeing, both geographically and in our end markets. A return to pre-pandemic levels of activity is driving healthy customer demand across most major geographies. This is reflected in the strong results we've seen throughout both the developed and high-growth markets and our strong order book growth, which continues to trend above revenue growth. While certain regions have implemented targeted lockdowns to address recent COVID-19 outbreaks, we're not seeing any widespread decline in our customer activity. Given the size and scope of our business, we're certainly not immune to ongoing supply chain constraints and inflationary pressures, but we're proactively addressing these challenges across Danaher, leveraging the Danaher Business System and tools such as daily management, and working closely with our customers and suppliers to mitigate the impact. We're also using DBS to accelerate price action and manage cost pressures. In fact, we've achieved nearly 150 basis points of price each of the last three quarters, which is approximately double our historical price realization. In Life Sciences, we're seeing robust demand across all major end markets. Lab and customer site access is holding at pre-pandemic levels, evidenced by more normalized customer productivity, equipment installations, and project initiation supported by a strong funding environment. Biopharma continues to be our strongest performing end market within the Life Sciences business, while shifts in treatment towards biologics as the standard of care and the accelerating focus on genomic therapies are driving significant investments in research, development, and production capacity across the sector. We believe we're well-positioned to support this work across our $7.5 billion bioprocessing franchise. We continue to see significant demand related to development and production of COVID-19 vaccines and therapeutics, and we expect this activity to persist longer term. Our customers are planning for ongoing production with the assumption that there will be an enduring need for effective treatment and prevention as the world transitions to regarding COVID-19 as an endemic virus. More broadly, our customers increasingly view the potential applications of new mRNA modalities, including vaccines and other therapeutics as an important area for future investments. In the clinical diagnostics market, patient volumes remain at or near pre-pandemic levels. Our customers have largely adapted their protocols and procedures to manage through recurring outbreaks, allowing them to continue wellness checks, routine screening, and other diagnostic procedures. While selective lockdowns are causing modest disruptions in certain regions like pockets of China and Europe, we're not experiencing any material widespread negative impact from these measures. In Molecular Diagnostics, global demand persists for Cepheid's point-of-care PCR respiratory test, further heightened as a result of the recent global surge of the Omicron variant. Additionally, we're seeing a more active respiratory season in the Northern Hemisphere, driving customers' preference for our four-in-one combination test, and we expect both of these trends to continue into the first quarter. In light of these dynamics and conversations we're having with our customers about their expectations for the upcoming year, we anticipate shipping the same number of respiratory tests in the first quarter as we did in the fourth quarter and approximately 50 million tests for all of 2022. In 2021, Cepheid placed a record 10,000 new GeneXpert systems bringing the total install base to more than 40,000 systems worldwide. The team's thoughtful approach to placing systems throughout the pandemic is focused on both the near and long-term value this technology can bring to our customers. More recently, we've seen several existing healthcare system and integrated delivery network customers adding new instruments at sites further out in their networks and closer to their patients, facilitating faster diagnostics and treatment decisions. The scalability and unique architecture of the GeneXpert, where the same test cartridges are used on higher and lower throughput instruments with the broadest test menu in the market, provides our customers with the confidence that they will achieve consistent reference lab-quality results, whether they're testing in an urgent care clinic or a central hospital lab. Looking ahead, with the assumption that COVID-19 will be in an endemic disease, we believe that the point-of-care molecular respiratory testing market will expand significantly from where it was prior to the pandemic. Given Cepheid's leading test menu and install base, combined with an advantaged positioning around speed, accuracy, and workflow, we believe Cepheid will continue to gain share in an endemic environment. Moving on to the applied markets, customer activity is largely back to pre-pandemic levels, which we see reflected in robust order rates for both consumables and equipment. Project-oriented activity is accelerating with an improving funding environment and more normalized site access, prompting the resumption of many projects and installations that were put on hold during the throes of the pandemic. Let's look ahead to our expectations for the first quarter and full year. Beginning with the first quarter of 2022, we will now include the impact of COVID vaccine and therapeutic-related revenue as part of our base business core revenue growth. This change is driven by our greater confidence in the durability of our COVID-related vaccine and therapeutic revenue as the virus turns endemic. For the first quarter and full year 2022, we expect our base business core revenue growth to be in the high single-digit percent range. Additionally, we expect to generate operating profit fall-through of 35% to 40% in the first quarter and for the full year 2022, up from historical and pre-pandemic rates between 30% and 35%. To wrap up, 2021 was another terrific year for Danaher. Our team successfully executed through a challenging environment to deliver outstanding financial performance, all while supporting our customers and directly contributing to the global fight against COVID-19. We're seeing the results of our purpose-driven portfolio transformation in action through faster growth, expanded margins, stronger cash flow, and higher recurring revenue. We're a better, stronger company today and there is tremendous runway ahead for us to continue building upon this foundation. With the Danaher Business System as our driving force, our talented team and resilient portfolio of businesses, we believe Danaher will continue generating sustainable long-term shareholder value for years to come. With that, I'll turn the call back over to Matt. Thank you.

Thanks, Rainer. That concludes our formal comments. Ashley, we're now ready to take questions.

We'll take our first question from Tycho Peterson with JPMorgan. Please go ahead.

Rainer, you guided for the base business to grow high single digits. Can you maybe just give us your latest thoughts on vaccine and therapies? I know you previously talked about this $2 billion backlog heading into the year. So have any of the assumptions around vaccines and therapies changed?

So just to confirm, that's right. For 2022, we're guiding the base business to high single digits. And no, our assumptions as it relates to the vaccine and therapeutics business have not changed. We saw continued strength in our orders. In fact, orders exceeded our sales here in Q4, and we continued to build backlog. At the same time, we have to say that from a roughly 70% comp, we were down about mid-teens in terms of the orders growth. Nonetheless, orders still outpace sales. We built backlog, and we're looking forward to roughly flat sales in the bioprocessing business for vaccine and therapeutic revenues in 2022. Now the core business, so in other words, the non-vaccine and therapeutic-related business for COVID, we expect that to continue to grow, of course, in the low double-digit area as has been the case here for many quarters.

And have any of the Aldevron assumptions changed? I know you previously talked about $500 million this year, growing greater than 20%.

They're right on the mark $500 million is a good number. That's kind of growth and slightly better than we expected here, closing the year off right around $400 million. So, Aldevron is right where we think we should be and performing at our expectations.

Okay. Maybe last one for McGrew. Environmental and applied operating margins were down quite a bit, I think, 410 basis points. Can you maybe just touch on what drove that decline?

Yes, sure. Like you said, it was down 410 here in the quarter. It's probably three things. I would say, first, that's probably the area that we accelerated the investment spend the most in the fourth quarter, given obviously, a pretty strong print here across the entire portfolio. I think we took an opportunity in the fourth quarter to kind of overcharge a little bit of the investment there at EAS. So I think that's probably the first thing. I think the second thing is the supply chain. The challenges I would say there are probably modestly more pronounced than they are elsewhere, Tycho. There's a high number of legacy products here that probably have more components. What's happening is the specialty components are a little bit harder to procure, especially in this environment. So we largely offset that with daily management and doing some spot buys and some other product redesigns, etc., but I think there are a few more supply chain issues there. The last thing is, if you think about there was a bit of a mix issue here too, with Trojan, which is a bit of a lower margin business being up, I think it was even north of 20% in the quarter. Despite that, though, the good news is, like I said, I think the team is doing a pretty good job using DBS to drive it from what we think and what we've seen here. It looks like, even because of all that, I think we took some share here in Q4 and definitely in Q1, and that's really a result of being able to get through those challenges and still meet customer demand.

And we would like to take our next question from Derik De Bruin with Bank of America. Please go ahead.

Thanks for taking my question. This is Mike calling for Derik. First of all, focus on Cepheid, both in '22 and post-pandemic. Given you're saying 19 million tests again in 1Q, it seems like you're assuming a pretty short dropoff in 2Q, 3Q. And then you set up pretty confident duration, the COVID being endemic now, the POC market expanding spiffy going forward being to keep market share. So could you give us some more color on continued market share gains, the 10,000 boxes you place this year, so what are your expectations going forward? And just is that $50 million testing, does that sort of assume that that's going to be the run rate beyond that? Or do you expect continued deterioration in COVID revenues offset by the other?

I'll start with, as you know, the situation around COVID is incredibly dynamic, right? It started with the assumptions that we made around Delta and then Delta spiked, and we thought that might become the dominant variant and then Omicron came 60 days ago, spiking. The environment is incredibly dynamic. But in the discussions that we have both with public health officials and also with our customers, I think there are a couple of takeaways. The first one is that we do think that COVID is going to turn endemic and a lot of public health officials will talk about the end of 2023, perhaps the beginning of '24, being that timeframe when we call it endemic with greater confidence. As we look at our customer feedback and what they see happening here, that's where we're triangulating for 2022 into the 50 million test area. We see our base business in 2022 growing at high single digits and eventually having as a result of a step-down from 60 to 50 in 2022. That's a 200 to 300 basis point headwind there. Still, as we think about that going forward beyond 2022, we think there will still be a large respiratory testing business, much larger than pre-pandemic in '23 and beyond. Once again, in the early days, this could change. It's so dynamic. But we're thinking that, that probably steps down again in 2023. Our working number for now is right around 30 million tests. So, as we think about the year 2023 and COVID testing, we see that going from 50 million in 2022 to perhaps 30 million in 2023, but that's a number that, of course, there are a lot of dynamics to consider. But that's sort of the planning number that we're working with. At the same time, as you think about 2023, we see our base business, of course, the primary aspect of our total business, continuing to grow off the strength of our portfolio. We've rated our growth rate and discussed that at several occasions, so we feel really good about how we're moving forward and like the setup.

Okay. Really appreciate the color there. And maybe one for Matt. You had some color on the pricing power going forward. I think you called out 100 basis points price in the fourth quarter and throughout the second half of the last three quarters. Could you comment on how much further runway do you see in '22 if we continue to be in an inflationary environment to pass on price to your customers? Any pushback you're seeing yet in any of the end markets? And just in general, the comments on how the fall-through in the business, labor pressure, logistics, obviously in the news a lot. So how are you navigating that this year and implications for margins for the year?

Yes. Sure. No, I mean, I think as far as price goes, like you said, we saw kind of 150 basis points here in Q4. We've seen that for the last couple of quarters. I think that's a pretty good placeholder to put in for '22. Teams over the last six months, we've been working harder to get that price, and I think you're seeing it show up. It's basically 2x the price we used to get, kind of, call it, five, six quarters ago. I guess it's a good place to start for '22. As far as margins go, we've provided guidance for '22 of 35% to 40% fall-through. That's down a little bit from where we stand at kind of more in that 40% to 45%. I think that 35% to 40% kind of incorporates a little bit of what you're talking about. It's in line with what we thought, frankly, our longer-term outlook was going to be. Even though we're seeing headwinds on the testing front this year, our COVID testing revenue is pretty much at the fleet average, which is why it's not a big step down for us. It's pretty much fleet average from a margin perspective. That helps as we navigate the headwinds.

And we'll take our next question from Vijay Kumar with Evercore. Please go ahead. Your line is open.

Hi, Rainer. Congrats on a solid print here. I guess one on just the guidance here, fiscal '22, some clarification. Your definition of core now includes vaccines, and I think that's comparable to how your largest peer looks at core organic. But vaccines, if I just understood you correctly, are flattish year-on-year, which means your base Danaher ex-vaccine is really growing at the very high end of high single. Is that the right way to think about the guidance here on the base business? And what's driving this trend? It looks like it's assuming perhaps bioprocessing growing double digits, that's well above your LRP. So I'm curious for some comments on bioprocessing.

Sure. Once again, just to level set, the base business includes bioprocessing for COVID vaccines and therapeutics. It's important to note that. In fact, we see the entire base business growing both for the quarter and the full year at high single digits. That's driven by a number of factors. One, as you just suggested, of course, the non-COVID bioprocessing business is still growing at the low double digits that we have seen here, and that continues to be strong. We also see our non-bioprocessing business, so as you think about our diagnostic businesses, our life science instruments and so forth, we see them growing very strongly on the back of the investments we've made around innovation, additional feet on the street, and really driving the growth here. Keep in mind that portfolio transformation that we've talked about has re-rated our base business growth, and we continue to see that. We saw that here in the two-year stack in 2021, and you're seeing that in the guide for 2022.

Understood. Now we have clarity on what the mid-single digit plus growth means, which is helpful. Maybe I can ask Matt about the 35% to 40% incremental margin share. Is that sustainable moving forward? My question is concerning your peers who benefited from COVID tailwinds. Is there a potential cliff or a transition year coming? It seems like Danaher does not face that cliff. Could you discuss the sustainability of the incremental margins and explain why the drop-down and co-tails shouldn't pose a challenge for Danaher?

Yes, I believe that's correct, Vijay. As I mentioned earlier, our COVID-related revenues from vaccines, therapeutics, and testing are more or less at an average level. The portfolio is being reassessed from a growth perspective, and we have also noted a change in the margin outlook. Previously, our margins were around 30% to 35%, but now we are seeing them at 35% to 40%. Looking ahead, I am quite confident about sustaining incremental margins in the 35% to 40% range. Although there may be some challenges, as observed in 2022 from a margin standpoint, I do not anticipate it to be excessively burdensome.

Good morning everybody. Congrats on a great year overall. But anyways, Rainer, I was hoping you could talk a little bit about M&A given that growth assets seemingly are out of favor in public markets fairly meaningfully. Is that kind of gone down into private markets at all and helped you out on the valuation side much? If you can talk about that in the pipeline, please.

Sure. First, to the environment that we see out there, this is an environment that over our history, we have thrived in, whether you want to call that anxiety or uncertainty or even in times of dislocation. We've always viewed this as a time of opportunity for ourselves. If you think back to the financial crisis now going back some years, we acquired SCIEX at that period, which turned out to be a fantastic asset. The team has done a wonderful job. If you think about some of the anxiety around Cepheid or the Pall deals, that has been something we're proud of how the teams have performed there and turned those businesses into real powerhouses. We sit here in this environment with a rock-solid portfolio, an outstanding team and a strong balance sheet, a great deal of optionality. We like that setup. As we think about our funnels, to your question, they continue to be adaptive. They cover the gamut, whether that's public or private, and we'll continue driving our M&A strategy and our bias towards allocating capital towards M&A as we have in the past. That will happen when that attractive end market, that first-class asset with competitive advantage meets our financial hurdles, as has always been the case. We like where we sit, and we like the setup.

That's helpful, Rainer. You talked about new product launches like Beckman. How has COVID impacted those launches? Were these things perhaps that were pushed back a little bit because of COVID? Were they on schedule with the customer response and ability to get out and see the customer with that product? Has that all been altered or changed? A little bit of color there would be helpful. And then I'll pass it on.

In our case, COVID has actually accelerated innovation for us. In the obvious sense, we were able to pull forward the GeneXpert COVID-only test and subsequently, very quickly thereafter, the four-in-one. Those are sort of the obvious examples. But at the same time, we've noted that we increased our R&D expenditures by 30% up to $1.7 billion, which has manifested in pulling forward innovation, accelerating it and getting those into the market. Examples include the Triple Quad 7500, most sensitive Triple Quad in the market, the ZenoTOF outstanding, and of course, the GT 450 pathology slide imaging, fantastic launches here, all of which was accelerated by the pandemic, and we were able to turn that into a real opportunity for us.

We'll take our next question from Dan Brennan with Cowen. Please go ahead. Your line is open.

I guess the first question, just on the vaccine therapeutics outlook now that you're including it in the base. We were assuming our model a pretty steep drop off in '23 and '24 just as we go from initial two-dose regimens down to boosters, and booster uptake looks good, probably not going to be nearly as good as the initial vaccine. So I guess, first question, is that reasonable to think there's going to be a healthy step down? And then number two, the fact that you're including it in the base, just wondering, I know you previously discussed IT but kind of high single digits. Is that still fair to think about the high single digits now that you've got vaccine and therapeutics in the base?

Sure. Well, let's start off with the reasoning for including vaccine and therapeutics in the base. This is driven by our belief of two things. One, that COVID-19 will be endemic in that there will be a continuous requirement for vaccination, and that is going to be a global requirement. We also think that new age groups will receive vaccinations more broadly in the world's kids in particular. There is a strong recurring demand there, and that was discussed at some of the previous questions. Looking ahead, if we back up a minute here and consider the longer term, I talked about our '22 guide here with high single-digit growth in our base business, and we talked about the 200 to 300 basis points of headwind coming from testing. As you think forward now, 2023 will be similar to 2022 as well. The base remains solid and resilient, keeping in mind our strong portfolio that drives growth and margin.

Excellent. And then maybe as a follow-up, just one more on bioproduction. Certainly, the low double-digit growth is impressive, particularly on the side of your business. Some of the CapEx that we've seen in the industry that is really accelerating. Rainer has talked about the margins of around 40% cost type of CapEx growth in '22 on top of 40% in '21. So I'm just wondering, could you give a little color or maybe the order book there, kind of what you're seeing? And are we in a period of hyper-investment or maybe that low double-digit could have some upside here over the next couple of years?

Sure. We continue to talk about the low double-digit growth rate for the non-COVID bioprocessing business. That's what we've seen for many quarters. We've also talked about the fact that our backlog continues to build there. The announcements that you're seeing in the market are important indicators of the strength of the industry and market itself. We can imagine with the breadth of our portfolio, our global reach that we play, if not all, the great majority of those kind of investments. Could there be upside? Sure, there could be. But we're looking at the order book and what's in hand and thinking about how that develops, and we'll continue to provide updates. For now, low double digits in the non-COVID processing business is a good planning number.

And we'll take our next question from Jack Meehan with Nephron Research. Please go ahead. Your line is open.

So one of the big questions we've been getting is the Fed is looking to start raising rates. Just would be great to get your thoughts around the durability of demand from biopharma customers? How much of a factor do you think higher rates could have on demand? And then finally, maybe any color on the mix between development and commercial and interplay on those two sides of the market?

Could you repeat the second question, please? It came through a little garbled.

Sure. Sorry. Just thoughts on how higher rates might influence demand from customers on the development side versus those with commercial products.

Understood. Well, let's start with the rates. It's early days, of course, and we'll see where those go. As we look at the markets that we play in, the impact of those rates could be different. Generally speaking, we see our end markets to perform and drive growth, even in a market where we see incrementally higher Fed rates. An example of that would be, if you look at biotech and aggregate, the cash positions in these companies are extraordinarily high. We continue to see strong investments there. We don't anticipate any near-term impact due to Fed rates in that particular area. That would overlap with the development part of your question. Those already in commercial production are out there driving growth and ensuring the penetration of the incredibly efficacious biologic drugs, not just in developed markets, but also in some of the higher growth markets. So we see demand drivers here going beyond any one country's monetary policy and continue to see that in a very positive light.

Great. Dan just asked about CapEx in the CDMO sector, and I want to inquire about the CapEx from the bioprocessing companies. During the Analyst Day, you mentioned your own CapEx of $1.5 billion. Some competitors are planning even greater investments in single-use technologies and bioprocessing in general. Considering the overall situation, can you discuss supply versus demand and share your thoughts on that?

Sure. The large CDMO investments you see there are really a derivative of the strength of the biotech market. These are typically smaller companies that don't want to invest their precious cash into manufacturing facilities, opting to outsource that to CDMOs. As we discussed, over the last five years, we've seen a huge increase in the number of projects in the funnel for monoclonal antibodies. If you think about nucleic acid therapies, there we've seen a 10 times increase in the development funnel. We're starting to see those work their way through the clinical trial process, which requires capacity. That's what the CDMO investments are about. Our customers are also CDMOs, and we're helping them build those capacities to take care of those developments going forward. We also continue to see drugs going commercial. For drugs going commercial, that's a 10 and 100 times increase in production capacity requirement. All of this, if you aggregate it, is what's pulling on our demand. We're confident in the investments we've made, not just for the short term, which is crucial to owning the supply bottlenecks as we work our way through the pandemic, but also for the long term. We want to be the partner of choice with the broadest portfolio to deliver to the point of impact around the globe with the necessary experts to help our customers get their drugs in the market more quickly and at lower costs.

Hi, Rainer. Thanks for taking the question. I just wanted to follow up on the bioprocessing piece. I know you touched a little bit about what the cadence could look like going forward. But that's certainly the question I think we get the most from investors. I wanted to circle back on it. It sounds like you feel really good about that underlying base business growing in the low double digits. And then the vaccine piece may be a little bit more of a variable. Can you talk, I guess, about the trajectory? It sounded like '22 is a decent proxy where maybe COVID comes down, and you shake out somewhere in the mid-high single digits as a whole for that kind of $7.5 billion business. I was just hoping you could talk a little bit about the puts and takes as we go through the next few years. Again, that vaccine piece comes down, but the base business seems like it's good enough to offset that and then some, but just wanted to get a better handle there.

I think that's right. As we look at 2022, I mentioned the COVID-related vaccine and therapeutic bioprocessing business, which will probably be roughly flat here in 2022. The assumption is we are starting to see the pandemic become endemic on the one hand. On the other hand, we are moving from 1.0 compounds to 2.0. Some vaccines and therapeutics are viewed as less efficacious in the current environment with the current variants, which makes those less of a factor. On the other hand, new monoclonal antibodies as therapeutics starting to be proposed show much higher efficacy with the variants. For those already in the market and effective, we're seeing recurring revenue as companies begin to recognize the ongoing need for booster shots globally. That's a good baseline to move forward and how to think about it. Our long-term guide around the bioprocessing business indicates that continues to be a high single-digit grower. That's how to think about it in '22. We think '23 will look a lot like '22 as well.

Great. No, that's helpful. And I know the order book typically takes orders within a year. Is any of that building into '23 yet? Or should we think about that as mostly a 12-month order book with conversations beyond that?

It's a 12-month order book in conversations beyond that.

Okay. And last one, just the same topic for Matt. The margin profile, COVID versus not for the bioprocessing, is pretty similar, right? I just want to double-check on that.

Yes. In bioprocessing, margin difference between COVID and not, is that what you're asking? Yes, there's no real difference. It's all depending on the mix of what goes in there, product-wise, but no margin profile wise it's the same.

And this will conclude today's Q&A portion for the call. I'll turn the call back over to Matt Gugino with any additional remarks. Thanks, Ashley, and thanks, everyone, for joining us on the call today. We're around all day for questions.

Thank you everybody.

And this does conclude today's program. Thank you for your participation. You may disconnect at any time.